WY-14 643, a selective PPARα Agonist, Induces Proinflammatory and Proangiogenic Responses in Human ocular Cells

International Journal of Toxicology

Volumn 29, Issue 5, 2010, Pages 496-504

  Zhang, Jin Zhong ^a   Ward, Keith W ^a  

^a BAUSCH AND LOMB   (United States)

Author keywords

angiogenesis; cytokine; inflammation; VEGF

Indexed keywords

DEXAMETHASONE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIRINIXIC ACID; RANTES; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; AORTA; ARTICLE; CONTROLLED STUDY; CORNEA EPITHELIUM; CYTOKINE RELEASE; ENDOTHELIUM CELL; EPITHELIUM CELL; HUMAN; HUMAN CELL; INFLAMMATION; KERATINOCYTE; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; UPREGULATION;

ANGIOGENESIS INDUCING AGENTS; CELLS, CULTURED; COLONY-STIMULATING FACTORS; CYTOKINES; EPITHELIUM, CORNEAL; EYE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; INTERLEUKINS; ORGAN SPECIFICITY; PEROXISOME PROLIFERATORS; PPAR ALPHA; PYRIMIDINES; RETINA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 78650036829     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581810376674     Document Type: Article

References (38)

1. Barabino S., Dana MR Dry eye syndromes. Chem Immunol Allergy. 2007 ; 92: 176-184.
2. Leonardi A., De Dominicis C., Motterle L. Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities. Curr Opin Allergy Clin Immunol. 2007 ; 7 (5). 429-435.
3. Kern TS Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007 ; 2007: 95103.
4. Nowak JZ Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep. 2006 ; 58 (3). 353-363.
5. Rizzo G., Fiorucci S. PPARs and other nuclear receptors in inflammation. Curr Opin Pharmacol. 2006 ; 6 (4). 421-427.
6. Schacke H., Schottelius A., Docke WD, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A. 2004 ; 101 (1). 227-232.
7. Renfro L., Snow JS Ocular effects of topical and systemic steroids. Dermatol Clin. 1992 ; 10 (3). 505-512.
8. Murata T., Hata Y., Ishibashi T., et al. Response of experimental retinal neovascularization to thiazolidinediones. Arch Ophthalmol. 2001 ; 119 (5). 709-717.
9. Murata T., He S., Hangai M., et al. Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000 ; 41 (8). 2309-2317.
10. Muranaka K., Yanagi Y., Tamaki Y., et al. Effects of peroxisome proliferator-activated receptor gamma and its ligand on blood-retinal barrier in a streptozotocin-induced diabetic model. Invest Ophthalmol Vis Sci. 2006 ; 47 (10). 4547-4552.
11. Vignali DA Multiplexed particle-based flow cytometric assays. J Immunol Methods. 2000 ; 243 (1-2). 243-255.
12. Schefe JH, Lehmann KE, Buschmann IR, Unger T., Funke-Kaiser H. Quantitative real-time RT-PCR data analysis: current concepts and the novel ''gene expression's CT difference'' formula. J Mol Med. 2006 ; 84 (11). 901-910.
13. O'Brien J., Wilson I., Orton T., Pognan F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem. 2000 ; 267 (17). 5421-5426.
14. Staels B., Koenig W., Habib A., et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature. 1998 ; 393 (6687). 790-793.
15. Biscetti F., Gaetani E., Flex A., et al. Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. Diabetes. 2008 ; 57 (5). 1394-1404.
16. Westergaard M., Henningsen J., Svendsen ML, et al. Modulation of keratinocyte gene expression and differentiation by PPARselective ligands and tetradecylthioacetic acid. J Invest Dermatol. 2001 ; 116 (5). 702-712.
17. Pozzi A., Ibanez MR, Gatica AE, et al. Peroxisomal proliferator-activated receptor-alpha-dependent inhibition of endothelial cell proliferation and tumorigenesis. J Biol Chem. 2007 ; 282 (24). 17685-17695.
18. Lemberger T., Staels B., Saladin R., Desvergne B., Auwerx J., Wahli W. Regulation of the peroxisome proliferator-activated receptor alpha gene by glucocorticoids. J Biol Chem. 1994 ; 269 (40). 24527-24530.
19. Bonazzi A., Mastyugin V., Mieyal PA, Dunn MW, Laniado-Schwartzman M. Regulation of cyclooxygenase-2 by hypoxia and peroxisome proliferators in the corneal epithelium. J Biol Chem. 2000 ; 275 (4). 2837-2844.
20. Moraes LA, Piqueras L., Bishop-Bailey D. Peroxisome proliferator- activated receptors and inflammation. Pharmacol Ther. 2006 ; 110 (3). 371-385.
21. Marx N., Sukhova GK, Collins T., Libby P., Plutzky J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 1999 ; 99 (24). 3125-3131.
22. Delerive P., De Bosscher K., Besnard S., et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem. 1999 ; 274 (45). 32048-32054.
23. Delerive P., Gervois P., Fruchart JC, Staels B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem. 2000 ; 275 (47). 36703-36707.
24. Xu X., Otsuki M., Saito H., et al. PPARalpha and GR differentially down-regulate the expression of nuclear factor-kappaBresponsive genes in vascular endothelial cells. Endocrinology. 2001 ; 142 (8). 3332-3339.
25. Drew PD, Xu J., Storer PD, Chavis JA, Racke MK Peroxisome proliferator-activated receptor agonist regulation of glial activation: relevance to CNS inflammatory disorders. Neurochem Int. 2006 ; 49 (2). 183-189.
26. Lee H., Shi W., Tontonoz P., et al. Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ Res. 2000 ; 87 (6). 516-521.
27. Hill MR, Clarke S., Rodgers K., et al. Effect of peroxisome proliferator-activated receptor alpha activators on tumor necrosis factor expression in mice during endotoxemia. Infect Immun. 1999 ; 67 (7). 3488-3493.
28. Mastyugin V., Aversa E., Bonazzi A., Vafaes C., Mieyal P., Schwartzman ML Hypoxia-induced production of 12-hydroxyeicosanoids in the corneal epithelium: involvement of a cytochrome P-4504B1 isoform. J Pharmacol Exp Ther. 1999 ; 289 (3). 1611-1619.
29. Kim J., Ahn JH, Kim JH, et al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp Eye Res. 2007 ; 84 (5). 886-893.
30. Kliewer SA, Forman BM, Blumberg B., et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A. 1994 ; 91 (15). 7355-7359.
31. Vu-Dac N., Schoonjans K., Laine B., Fruchart JC, Auwerx J., Staels B. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem. 1994 ; 269 (49). 31012-31018.
32. Scatena R., Bottoni P., Vincenzoni F., et al. Bezafibrate induces a mitochondrial derangement in human cell lines: a PPARindependent mechanism for a peroxisome proliferator. Chem Res Toxicol. 2003 ; 16 (11). 1440-1447.
33. Selim E., Frkanec JT, Cunard R. Fibrates upregulate TRB3 in lymphocytes independent of PPAR alpha by augmenting CCAAT/ enhancer-binding protein beta (C/EBP beta) expression. Mol Immunol. 2007 ; 44 (6). 1218-1229.
34. Zhang X., Tanaka N., Nakajima T., Kamijo Y., Gonzalez FJ, Aoyama T. Peroxisome proliferator-activated receptor alpha-independent peroxisome proliferation. Biochem Biophys Res Commun. 2006 ; 346 (4). 1307-1311.
35. Colucciello M. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch Ophthalmol. 2005 ; 123 (9). 1273-1275.
36. Ryan EH Jr, Han DP, Ramsay RC, et al. Diabetic macular edema associated with glitazone use. Retina. 2006 ; 26 (5). 562-570.
37. Sotiropoulos KB, Clermont A., Yasuda Y., et al. Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain. FASEB J. 2006 ; 20 (8). 1203-1205.
38. Keech AC, Mitchell P., Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007 ; 370 (9600). 1687-1697.